Loading patent…
AssigneesNational University Corporation Kanazawa University, Medical Corporation Saneikai, National University Corporation Tokai National Higher Education and Research System, Rohto Pharmaceutical Co., Ltd.
InventorsKunio MATSUMOTO, Ryu IMAMURA, Yukio KATO, Yusuke MASUO, Shigehiko MIZUTANI, Hiroaki KAJIYAMA, Masato YOSHIHARA
Estimating the term…
The present invention addresses the problem of providing a prophylactic and/or therapeutic agent for hypertensive disorders of pregnancy, which has a physical property or a molecular weight that inhibits the passage through the placental barrier, has a pharmacological activity that mimics the original physiological function of the placenta and therefore has fewer adverse side effects, is safe for a mother body and a fetus, is stable for a long period, and can exert the efficacy thereof in vivo for a long period. The present invention is a prophylactic/therapeutic agent for pregnancy-induced hypertension, which comprises aminopeptidase A (APA) as an active ingredient, the prophylactic/therapeutic agent being characterized in that the APA is bound to an immunoglobulin Fc region through a peptide linker.
A prophylactic and/or therapeutic agent for pregnancy-induced hypertension, comprising an aminopeptidase A (APA) as an active ingredient,
An aminopeptidase A (APA)-Fc fusion protein, wherein the aminopeptidase A (APA) binds to an immunoglobulin Fc region via a peptide linker comprising at least one amino acid sequence selected from the group consisting of SEQ ID NOs:
A method of treating pregnancy-induced hypertension in a subject, comprising administering to the subject an effective amount of an aminopeptidase A (APA)-Fc fusion protein comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:
Dependencies are inferred from the claim text.